Akriveia Therapeutics (Series A)

Funding Details
Awarder
Inbox
Date Award
October 12, 2016
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$7,500,000
Company Info
Founders
Professor John Williams, Professor Ulrich Rodeck
Company Description
Akriveia Therapeutics is discovering and developing the next generation of cancer immunotherapies. Akriveia's new agents offer the promise of a safer and more efficacious approach to harness a patient's own immune system to fight cancer.
Market
Cancer Immunotherapy
Location
Skillman, NJ, USA
Links
Back to Home Back to Biotechnology Deals View Funding Announcement